Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_02157 |
| Species: | Homo sapiens |
| Position : | chr6:31350000-31355000 |
| Year: | 2025 |
| Title: | Super-Enhancer-Driven HCG20 Promotes Pulmonary Hypertension Through U2AF2 Splicing. |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 40433695 |
| Tissue: | lung |
| Tissue Ontology ID: | UBERON:0002048 |
| Cell Source: | Human Pulmonary Artery Endothelial Cells |
| Cell Type: | pulmonary artery endothelial cell |
| Cell Ontology ID: | CL:1001568 |
| Experiment Type: | Functional perturbation assay, TF binding assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling |
| High Throughput Method: | ChIP-seq, RNA-seq; RNA-seq; ChIP-seq |
| Low Throughput Method: | ChIP-RT-qPCR, CRISPR Knockout, RT-RT-qPCR; CRISPR-Cas9 endogenous deletion/editing; Luciferase reporter assay; ChIP-qPCR; ChIP; RT-qPCR; Reporter assay |
| Target gene : | HCG20 |
| TF name : | USF2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| USF2 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | pid | 37 |